


Anacor Pharmaceuticals Announces First Quarter 2011 Financial Results Conference Call and Webcast
PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the first quarter ended March 31, 2011, on Thursday May 5, 2011 at approximately 7:00 a.m. ET / 4:00 a.m. PT. The announcement will be followed by a conference call at 8:00 a.m. ET / 5:00 a.m. PT during which management will discuss the companya™s financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call and providing the conference ID 63098653. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the companya™s website at [ www.anacor.com ] and will be available for three months following the call.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds which are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and atopic dermatitis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit [ http://www.anacor.com ].